Skip to main content
. Author manuscript; available in PMC: 2009 Oct 1.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):971–981. doi: 10.1002/pds.1637

Table 3.

Frequency (%) and duration (mean±SE) (days) of most commonly coadministered QT-prolonging drugs1

graphic file with name nihms76314t1.jpg
1

Percentage represents number of patients receiving specified drug combination relative to all patients receiving coadministered QT-prolonging drugs

2

Numbers in parentheses refer to risk of drug associated torsade de pointes as detailed in Table 1.

HHS Vulnerability Disclosure